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Abstract
Aberrant DNA methylation profiles have been implicated in numerous cardiovascular dis-
eases; however, few studies have investigated how these epigenetic modifications contrib-
ute to stroke recurrence. The aim of this study was to identify methylation loci associated
with the time to recurrent cerebro- and cardiovascular events in individuals of European and
African descent. DNA methylation profiles were generated for 180 individuals from the Vita-
min Intervention for Stroke Prevention clinical trial using Illumina HumanMethylation 450K
BeadChip microarrays, resulting in beta values for 470,871 autosomal CpG sites. Ethnicity-
stratified survival analyses were performed using Cox Proportional Hazards regression
models for associations between each methylation locus and the time to recurrent stroke or
composite vascular event. Results were validated in the Vall d’Hebron University Hospital
cohort from Barcelona, Spain. Network analyses of the methylation loci were generated
using weighted gene coexpression network analysis. Primary analysis identified four signifi-
cant loci, cg04059318, ch.2.81927627R, cg03584380, and cg24875416, associated with
time to recurrent stroke. Secondary analysis identified three loci, cg00076998, cg16758041,
and cg02365967, associated with time to composite vascular endpoint. Locus cg03584380,
which is located in an intron of ZDHHC6, was replicated in the Vall d’Hebron University Hos-
pital cohort. The results from this study implicate the degree of methylation at cg03584380
is associated with the time of recurrence for stroke or composite vascular events across two
ethnically diverse groups. Furthermore, modules of loci were associated with clinical traits
and blood biomarkers including previous number of strokes, prothrombin fragments 1 + 2,
thrombomodulin, thrombin-antithrombin complex, triglyceride levels, and tissue
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plasminogen activator. Ultimately, these loci could serve as potential epigenetic biomarkers
that could identify at-risk individuals in recurrence-prone populations.
Introduction
Ischemic strokes account for 87% of all strokes and are heterogeneous, multifactorial diseases
comprising genetic and environmental contributions. Of the approximately 795,000 incident
stroke cases annually in the United States, approximately 25% are recurrent events [1]. Indi-
viduals experiencing an ischemic stroke are at high risk of having a recurrent stroke or devel-
oping cardiovascular diseases including myocardial infarction (MI), coronary heart disease, or
vascular death. Only a proportion of the estimated 37.9% heritability for ischemic stroke [2] is
accounted for from genetic variants identified in genome-wide association studies, suggesting
other mechanisms, such as epigenetic modifications, could comprise some of the remaining
heritability for ischemic stroke and stroke recurrence risk.
Epigenetics, such as DNA methylation, refer to chemical modifications of DNA structure
that can be maintained over cellular generations [3] and serve to propagate cellular memory
[4]. Abnormal DNA methylation patterns have been implicated in a number of cardiovascular
diseases [5, 6]; however, few studies have investigated these epigenetic contributions to stroke
recurrence [7–9]. The aim of this study was to elucidate DNA methylation loci associated with
the time to vascular events, including recurrent stroke, MI, and death. Single locus and com-
prehensive loci networks were analyzed in 180 individuals from the Vitamin Intervention for
Stroke Prevention (VISP) clinical trial and further validated in the independent Vall d’Hebron
University Hospital cohort. Findings from this study support the utility of epigenetic marks as




The institutional review boards (IRBs) of Wake Forest University School of Medicine, the Uni-
versity of North Carolina at Chapel Hill School of Medicine, and individual recruitment sites
approved the VISP clinical trial study protocol. All VISP participants provided written,
informed consent. A subset of 2,100 participants agreed to be included in subsequent genetic
studies. IRB approval from the University of Virginia and East Carolina University was
obtained for the genetic and epigenetic components.
Discovery cohort: Vitamin Intervention for Stroke Prevention (VISP)
clinical trial
VISP was a multi-centered, double-blinded, randomized and controlled clinical trial that
enrolled participants aged 35 years or older with baseline homocysteine levels at or above the
25th percentile and was designed to determine whether pyridoxine (B6), cyanocobalamin
(B12), and folic acid (B9) supplementation reduced recurrent cerebral infarction, MI, or fatal
coronary heart disease (CHD) [10]. Participants were enrolled within 120 days of suffering a
non-disabling cerebral infarction, assigned a daily B vitamin high-dose or low-dose formula-
tion, and followed for two years. While ischemic subtype was not adjudicated, based on inclu-
sion/exclusion criteria [10], the VISP enrollment stroke was most likely a small-vessel
(lacunar) infarct.
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A subset of 2,100 VISP participants consented for inclusion in genetic studies of which,
methylation data were generated for 204 participants. Upon quality control (QC), the methyla-
tion profiles of 180 individuals were used in subsequent analyses, including 76 individuals of
African descent (AFR) and 104 of European descent (EUR). Individual level genetics and epi-
genetics data is considered sensitive controlled data and cannot be shared publicly, as specified
by the IRBs of Wake Forest University School of Medicine, the University of North Carolina at
Chapel Hill School of Medicine, and the University of Virginia School of Medicine, along with
the NIH Data Access Committee. Controlled-access data can only be obtained if a user has
been authorized by the appropriate Data Access Committee. The individual level Genomics
and Randomized Trials Network (GARNET) VISP data are available in the database of Geno-
types and Phenotypes (dbGaP) (Accession: phs000343.v3.p1) and can be requested through
the dbGaP Authorized Access System (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=
login). The authors will also share the data on request.
Replication cohort: The Vall d’Hebron University Hospital cohort
From a cohort of 1,900 patients with stroke from Vall d’Hebron University Hospital (Barce-
lona, Spain), 28 subjects with composite vascular recurrence events were selected. Of these par-
ticipants, 18 had a recurrent ischemic stroke. Composite vascular recurrence was described as
new ischemic stroke, MI, peripheral vascular disease, or cardiovascular death and was detected
through telephone interviews every three months or direct clinical visit. The epigenome-wide
methylation profiles were generated using Illumina Infinium 450k BeadChip microarrays. The
profiles were processed in a single working batch and preprocessing, correction, normalization
steps, and QC was performed using R, as previously described [8]. The epigenetics and genet-
ics summary data used for replication will be shared for research studies on approval of the
principal investigators of the GRECOS (Genotyping Recurrence Risk of Stroke) cohort.
Stroke recurrence and composite vascular event definition
The primary vascular endpoint analyzed in the current study was an incident recurrent stroke
during the VISP trial (VISP recurrent stroke). VISP recurrent stroke was defined as an acute
neurological ischemic event, requiring a sudden onset of symptoms lasting at least 24 hours, as
reported on the Follow-up Stroke Symptoms (FSS) form or as determined by the VISP End-
point Review Committee [10].
A composite vascular event was examined as a secondary endpoint and was defined as fatal
coronary heart disease, a non-fatal hospitalized MI and resuscitation for cardiac collapse, coro-
nary bypass surgery, coronary angioplasty, or a VISP recurrent cerebrovascular event.
Methylation data generation
Genomic DNA was extracted from whole blood samples of the VISP participants, as previously
described [9]. Briefly, the DNA was denatured and bisulfite-converted using Zymo EZ DNA
Methylation Kits (Zymo Research Corp., Irvine, CA). Illumina Infinium Human Methyla-
tion450k BeadChip microarrays were used to interrogate CpG sites across the genome and the
resulting intensity files were analyzed using GenomeStudio. Beta scores were generated as the
ratio of methylated intensities divided by the sum of the methylated and unmethylated intensi-
ties (i.e. the proportion of total signal from the methylation-specific probe). Probes were
removed if they failed to hybridize (detection p>5%) or if they were located on sex chromo-
somes. The filtered beta scores underwent stratified quantile normalization with theminfi
package in R [11–13]. A total of 470,871 autosomal CpGs were used in subsequent analyses.
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Covariate generation
To account for population substructure, a principal component analysis was performed using
KING software [14] on VISP genotype data. The top four and ten principal components (PCs)
were generated and used as covariates in the survival analysis for the EUR population and AFR
population, respectively. Batch effect was adjusted for using factor variables indicative of meth-
ylation data generation round, while cellular heterogeneity due to the variation in cell popula-
tion proportions within whole blood samples was controlled for using cell proportion
estimates generated by the estimateCellCounts function inminfi [12, 15–17]. This function
generates cell counts for B-lymphocytes, CD4+ and CD8+ T-lymphocytes, natural killer cells,
granulocytes, and monocytes.
Statistical analysis
Baseline characteristics of the study participants with and without recurrent stroke were com-
pared using t-tests and χ2 tests for continuous and categorical traits, respectively, by each eth-
nic stratum.
Survival analyses utilizing Cox Proportional Hazards (PH) regression models were per-
formed for the time in days to VISP recurrent stroke or composite vascular event for both
AFR and EUR participants independently. The degree of methylation was the exposure and
the models adjusted for age, sex, PCs, batch effect, treatment arm, and cellular proportions.
The replication cohort adjusted for age, sex, the top two PCs, cell heterogeneity proportions,
and batch effect. Statistical significance was calculated at p�1.06e-07 (= 0.05/470871 total
number of loci) for the discovery cohort. Statistical power ranged from 0.5847 to 0.7466 based
on analysis phenotype [18]. A significance threshold of p�7.14e-03 (= 0.05/7) was determined
for the look-up analysis in the replication cohort.
Weighted Gene Co-expression Network Analysis (WGCNA) [19] was used to identify net-
works or modules of highly correlated DNA methylation loci and blood biomarkers or clinical
traits (n = 27 traits; S1 Table). Modules were calculated using the blockwise module function
in the WGCNA R package. Outlier samples were identified and removed to ensure reliable
network construction. An appropriate soft threshold power was calculated for each stratum. A
soft thresholding power of 20 in the AFR cohort and 26 in the EUR cohort was determined at
a threshold�0.8. These parameters were used in a signed-hybrid network model with the min-
imum number of loci set to 30 and a maximum block size set to 10,000. The loci comprising
each module were represented by a weighted average, which is indicative of the first principle
component in the analysis.
Statistical significance was calculated as p�3.93e-09 (= 0.05/(470871 loci�27 traits)), while
the suggestive threshold was set at p<1.00e-03.
Gene ontology (GO) term enrichment was performed using GOrilla (Gene Ontology
enRIchment anaLysis and visuaLizAtion) [20, 21] for the seven significant loci identified in
the survival analysis with p�1.06e-07. Statistical significance for GO term enrichment
included terms with a false discovery rate (FDR) q-value� 0.05.
To further evaluate the biological mechanisms of statistically and marginally significant
(p<1.00e-06) CpG sites from the AFR VISP recurrent stroke and composite vascular event
analyses, the Functional Mapping and Annotation of Genome-Wide Association Studies
(FUMA GWAS) version 1.3.6a [22] online platform and the GENE2FUNC process was uti-
lized. The EUR composite vascular event analysis resulted in two CpGs that met or exceeded
the suggestive threshold and therefore, functional mapping was not performed. A total of 36
(AFR VISP recurrent stroke) and 30 (AFR VISP composite vascular event) gene names were
combined, resulting in 57 unique gene names uploaded into FUMA for evaluation of gene
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expression and enrichment of differentially expressed gene sets in tissues from the Genotype-
Tissue Expression (GTEx) 8 RNA sequencing data [23]. Upon filtering by ENSEMBL identifi-
ers, 53 genes were used in the GTEx analyses. A multiple testing correction was performed
using a Benjamini-Hochberg adjustment. Statistical significance was calculated using a p-
threshold of p<0.05.
Results
The baseline characteristics of 76 AFR and 104 EUR VISP study participants with and without
recurrent stroke were compared using χ2 and t-tests for categorical and continuous variables,
respectively, and are presented in Table 1. Of these individuals, 28 AFR and 32 EUR partici-
pants had an incident VISP recurrent stroke. In the AFR individuals, the average baseline age
of those experiencing a recurrent stroke was five years older compared to those not having a
recurrent stroke (65 years versus 60 years; p = 0.047). Of particular interest, those individuals
having a VISP recurrent stroke had a more severe enrollment stroke compared to the non-
recurrent control group, as measured on the modified Rankin stroke scale (RSS). While the
enrollment criteria for VISP included mild-to-moderate RSS scores of 0–3, 35.7% of those suf-
fering a recurrent stroke during VISP follow-up experienced an enrollment stroke with a RSS
of 3, which is indicative of moderate disability, while 10.4% of the non-recurrent individuals
had a similar enrollment stroke severity. Although not as extreme, VISP EUR participants had
similar baseline age differences (70 years versus 68 years for VISP recurrence and nonrecur-
rence, respectively), as well as enrollment stroke severity compared with AFR participants.
Approximately 44% of EUR VISP participants who experienced a recurrent stroke had RSS of
0 or 1, compared to nearly 71% of participants in the non-recurrent group having a similar
score indicative of no significant disability (Table 1).
Ethnicity-stratified Cox PH analyses identified a total of seven methylation loci associated
with time to event for recurrent stroke or composite vascular event (Tables 2 and 3). Four sta-
tistically significant loci were identified for days to VISP recurrent stroke. The most significant
association was observed for cg04059318 (HR [95% CI] = 7.19 [3.55–14.57]; p = 4.52e-08),
located on chromosome 10. Three additional loci, ch.2.81927627R (HR = 2.72 [1.89–3.93];
p = 9.11e-08), cg03584380 (HR = 5.41 [2.91–10.06]; p = 9.66e-08), and cg24875416 (HR = 2.43
[1.75–3.37]; p = 9.82e-08) were also implicated in the AFR recurrent stroke analysis (Table 2;
Fig 1). There were no statistically significant loci in the days to VISP stroke recurrence analysis
in EUR. cg03584380, an intronic locus of ZDHHC6, was the only locus to remain significant in
the replication cohort from Vall d’ Hebron University in Barcelona (HR = 1.83(1.21–2.77);
p = 4.00e-03; Table 2). The ENCODE annotation and gene position for cg03584380 is pre-
sented in Fig 2. For the time to composite vascular event analysis, cg00076998 (HR = 5.58
[2.98–10.44]; p = 7.87e-08) and cg16758041 (HR = 3.44 [2.18–5.43]; p = 1.04e-07) were identi-
fied in AFR (Fig 3; Table 3), while cg02365967 (HR: 0.42 [0.31–0.58]; p = 8.08e-08) was identi-
fied in the EUR stratum (Fig 4; Table 3). Using Schoenfeld residual tests, we did not observe
any evidence of violation to the proportional hazards assumptions for any of the base models
indicated by a global p<0.05 (p = 0.084 for AFR VISP recurrent stroke, p = 0.059 for AFR
composite vascular endpoint, p = 0.320 for EUR VISP recurrent stroke, and p = 0.121 for EUR
composite vascular endpoint analyses).
GO analysis was performed on the eight genes located closest to the significant loci identi-
fied in the survival analyses (PTEN, KLLN, PIK3CB,HERC2, CTNNA2, ZDHHC6, STRIP1,
and NDUFB6). Nine terms describing biological processes and molecular function met a mod-
est significance threshold (p�1.00e-03), including prepulse inhibition (GO: 0060134;
p = 8.22e-06), brain morphogenesis (GO: 0048854, p = 2.87e-05), and axonogenesis (GO:
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N 28 48 32 72
Age, yrsb 65.18 (11.54) 60.40 (8.94) 0.047 70.03 (11.48) 68.01 (10.81) 0.391
Sex
Male (%) 17 (60.7) 29 (60.4) 1.000 18 (56.2) 39 (54.2) 1.000
Female (%) 11 (39.3) 19 (39.6) 14 (43.8) 33 (45.8)
Treatment Arm
High-dose (%) 14 (50.0) 22 (45.8) 0.910 14 (43.8) 40 (55.6) 0.368
Low-dose (%) 14 (50.0) 26 (54.2) 18 (56.2) 32 (44.4)
Current Smoker (%) 8 (28.6) 13 (27.1) 1.000 3 (9.4) 9 (12.5) 0.898
Body Mass Index, kg/m2 29.01 (5.45) 30.35 (6.65) 0.370 29.64 (7.21) 28.52 (5.68) 0.403
Diabetes mellitus (%) 9 (32.1) 20 (41.7) 0.562 13 (40.6) 21 (29.2) 0.356
Myocardial infarction (%) 3 (10.7) 1 (2.1) 0.274 0 (0.0) 4 (5.6) 0.419
Recurrent stroke ever (%) 28 (100.0) 16 (33.3) <0.001 32 (100.0) 15 (20.8) <0.001
PNS
0 12 (44.4) 32 (66.7) 0.139 19 (61.3) 57 (79.2) 0.212
1 8 (29.6) 13 (27.1) 6 (19.4) 10 (13.9)
2 4 (14.8) 2 (4.2) 5 (16.1) 4 (5.6)
3 2 (7.4) 1 (2.1) 1 (3.2) 1 (1.4)
4 1 (3.7) 0 (0.0) 0 (0.0) 0 (0.0)
RSS
0 2 (7.1) 7 (14.6) 0.001 4 (12.5) 17 (23.6) 0.071
1 16 (57.1) 20 (41.7) 10 (31.2) 34 (47.2)
2 0 (0.0) 16 (33.3) 14 (43.8) 16 (22.2)
3 10 (35.7) 5 (10.4) 4 (12.5) 5 (6.9)
Hypertension (%) 24 (85.7) 42 (87.5) 1.000 28 (87.5) 56 (77.8) 0.373
Systolic Blood Pressure, mmHg 144.34 (20.43) 143.65 (20.16) 0.886 146.77 (19.29) 140.11 (19.67) 0.112
Diastolic Blood Pressure, mmHg 80.09 (9.89) 82.05 (10.12) 0.414 81.34 (8.67) 78.14 (9.81) 0.115
Creatinine, mg/dL 1.16 (0.39) 1.41 (0.68) 0.076 1.26 (0.55) 1.11 (1.00) 0.44
Total cholesterol, mg/dL 190.09 (53.10) 212.85 (55.33) 0.107 206.48 (37.67) 201.93 (48.04) 0.641
High-density lipoprotein, mg/dL 42.17 (10.76) 51.76 (16.99) 0.016 45.17 (13.78) 46.59 (16.10) 0.676
Triglycerides, mg/dL 146.95 (105.06) 162.46 (138.70) 0.65 193.83 (110.43) 201.89 (193.05) 0.834
Total plasma homocysteine,
μmol/L
15.20 (5.16) 14.95 (6.62) 0.862 15.58 (6.85) 16.82 (12.82) 0.607
B6, nmol/L 36.08 (33.36) 22.33 (20.91) 0.042 29.99 (19.26) 43.03 (50.34) 0.18
B12, pmol/L 421.63 (226.23) 418.30 (190.21) 0.947 354.97 (132.03) 313.50 (124.92) 0.144
Folate, ng/mL 31.92 (32.59) 21.85 (9.26) 0.057 20.84 (10.59) 24.65 (11.25) 0.122
C-reactive protein, mg/L 12.49 (8.92) 12.64 (10.26) 0.953 13.50 (8.41) 11.37 (8.92) 0.277
Prothrombin fragments 1+2,
nmol/L
0.99 (0.56) 1.25 (1.42) 0.386 1.14 (0.63) 1.14 (1.28) 0.996
Thrombin-antithrombin
complex, μg/L
9.11 (12.52) 5.26 (3.49) 0.099 6.47 (8.94) 6.42 (6.73) 0.98
Thrombomodulin, ng/mL 10.33 (18.47) 11.74 (25.00) 0.84 10.66 (22.63) 8.34 (12.82) 0.588
Tissue plasminogen activator, ng/
mL
15.42 (10.61) 15.78 (19.58) 0.933 14.32 (15.14) 18.07 (21.12) 0.419
(Continued)
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0007409, p = 6.94e-04) (S2 Table). To further elucidate any biological implications of our find-
ings, we performed functional annotation and mapping of the 57 unique genes with suggestive
(p<1.00E-06) CpG loci from the Cox PH results on AFR VISP recurrent stroke and composite
vascular endpoint analyses. Tissue analysis on 53 specific types from the GTEx project,
revealed statistically significant differential down-regulated expression in the pancreas (padj =
3.05e-08), putamen basal ganglia (padj = 2.42e-06), left ventricle of the heart (padj = 1.54e-05),
liver (padj = 8.75e-05), amygdala (padj = 1.50e-04), caudate basal ganglia (padj = 2.30e-04), hip-
pocampus (padj = 3.52e-04), nucleus accumbens basal ganglia (padj = 9.30e-04), anterior cingu-
late cortex BA24 (padj = 5.93e-04), substantia nigra (padj = 6.02e-03), skeletal muscle (padj =
2.72e-02), whole blood (padj = 2.91e-02), hypothalamus (padj = 2.93e-02), and the cortex (padj =
3.89e-02) (Fig 5, Table 4), when compared to the background gene set from GTEx v8.
To evaluate comprehensive networks of methylation loci associated with stroke related clin-
ical traits, WGCNA was performed in the two ethnic strata upon outlier removal, which
resulted in 100 EUR and 73 AFR participants included. Twenty-seven traits, including baseline
biomarker levels, stroke risk factors, and outcome statuses were included in the analyses
(Table 1; S1 Table). In the AFR stratum, 106 modules were produced, of which six were
observed in significant module-clinical trait associations (p�3.93e-09; Table 5). The significant
associations observed were between modules and the previous number of strokes experienced
before VISP enrollment (r = -0.90; 5.00e-27), prothrombin fragments 1 + 2 (r = -0.79;
p = 8.00e-17), thrombomodulin (r = -0.77; 1.00e-15), thrombin-antithrombin complex (r =
-0.73; p = 3.00e-13), triglyceride levels (r = -0.71; p = 2.00e-12), and tissue plasminogen activa-
tor (r = -0.68; p = 3.00e-11). Additional module associations in AFR were detected with traits
and outcomes including MI, hypertension, thrombomodulin, and thrombin-antithrombin
complex. In the EUR analysis, 27 modules were produced; however, no module-trait associa-
tions observed met the significance threshold. Notable nominal associations in this stratum












von Willebrand Factor, IU/L 1551.15 (747.11) 1222.32 (616.71) 0.053 1284.78 (652.09) 1315.66 (874.32) 0.871
ap-value calculated using t-tests and χ2 for continuous and categorical traits, respectively.
bContinuous traits described as mean (SD). Categorical traits described as N (%).
Abbreviations: AFR- African descent stratum; EUR- European descent stratum; PNS- number of strokes prior to VISP enrollment; RSS- modified Rankin stroke scale.
https://doi.org/10.1371/journal.pone.0254562.t001
Table 2. Significant methylation loci associated with time to VISP recurrent stroke in AFR (p�1.06e-07).
aDiscovery Cohort: VISP Replication
Locus CHR:BP Locus Location Gene Mean Beta Value HR (95% CI) P P
cg04059318 10:89622526 TSS1500; Exon 1 PTEN; KLLN 0.07 7.19 (3.55–14.57) 4.52E-08 0.665
ch.2.81927627R 2:82074116 Downstream CTNNA2 0.09 2.72 (1.89–3.93) 9.11E-08 0.178
cg03584380 10:114206433 Intron 1 ZDHHC6 0.06 5.41 (2.91–10.06) 9.66E-08 0.004
cg24875416 1:110577936 Intron 1 STRIP1 0.08 2.43 (1.75–3.37) 9.82E-08 0.784
aDiscovery model adjusts for age, sex, top 10 genetic principal components, treatment arm, batch effect, and estimated cellular proportions.
Abbreviations: CHR- chromosome; BP-base position (hg19); TSS1500- covers from 200 to 1500 nucleotides upstream of transcriptional start site (TSS); HR-hazard
ratio; CI- confidence interval.
https://doi.org/10.1371/journal.pone.0254562.t002
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total plasma homocysteine. Only two loci identified in the Cox PH models were included in
any of the modules. While identified in the AFR survival analyses, cg04059318 and
cg24875416 were included in the turquoise module for EUR. Interestingly, this was one of two
modules nominally associated with VISP recurrent stroke or composite vascular endpoint
(r = 0.43, p = 8.00e-06 and r = 0.44, p = 5.00e-06, respectively) (Table 5).
Discussion
To the best of our knowledge, this study represents the first epigenome-wide association study
evaluating association between time to recurrent stroke (or composite vascular event) and the
degree of methylation. This study was performed in a subset of the VISP clinical trial
Table 3. Significant methylation loci associated with time to VISP composite vascular endpoint (p�1.06e-07).
aDiscovery Cohort: VISP Replication
Strata Locus CHR:BP Locus Location Gene Mean Beta Value HR (95% CI) P P
AFR cg00076998 3:138553170 Upstream PIK3CB 0.06 5.58 (2.98–10.44) 7.87E-08 0.608
cg16758041 9:32573371 TSS200 NDUFB6 0.07 3.44 (2.18–5.43) 1.04E-07 0.738
EUR cg02365967 15:28473380 Exon 35 HERC2 0.94 0.42 (0.31–0.58) 8.08E-08 0.163
aDiscovery model adjusts for age, sex, genetic principal components (first 4 in EUR; first 10 in AFR), treatment arm, batch effect, and estimated cellular proportions.
Abbreviations: CHR- chromosome; BP-base position (hg19); TSS200- region from the transcriptional start site (TSS) to 200 nucleotides upstream of TSS; HR-hazard
ratio; CI- confidence interval.
https://doi.org/10.1371/journal.pone.0254562.t003
Fig 1. Epigenome-wide Manhattan plot for time (days) to VISP recurrent stroke survival analysis in AFR. Each point corresponds to the -log10(P-value) for a
CpG site at its specific chromosome location (y-axis). Horizontal line is indicative of epigenome-wide significance threshold (p� 1.06e-07).
https://doi.org/10.1371/journal.pone.0254562.g001
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participants, providing a diverse cohort of individuals of both AFR and EUR descent. The
inclusion of individuals of AFR descent is a strength of this study, since this population is 60%
more likely to experience a recurrent stroke within two years compared to individuals of EUR
descent, albeit likely mediated by stroke risk factors and comorbidities [24]. Seven loci reached
Fig 2. ENCODE annotation of cg03584380 on intron 1 of ZDHHC6. The annotation for cg03584380 includes CpG islands, cell line chromatin state (ChromHMM),
H3K27Ac marks, and cell line methylation at CpG sites on the Methyl450 Bead Arrays from ENCODE/Hudson Alpha Institute for Biotechnology (ENCODE/HAIB;
bright blue, purple, and orange CpGs correspond to unmethylation, partially methylated, and methylated states, respectively).
https://doi.org/10.1371/journal.pone.0254562.g002
Fig 3. Epigenome-wide Manhattan plot for AFR time to composite vascular event. Horizontal line is indicative of epigenome-wide significance threshold (p�
1.06e-07).
https://doi.org/10.1371/journal.pone.0254562.g003
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or exceeded a Bonferroni corrected significance threshold, with cg03584380 statistically signif-
icant in AFR stroke recurrence and validated upon replication in the Vall d’Hebron University
Hospital cohort. While similar trends were observed across phenotypes due to the strong cor-
relation between the primary (VISP recurrent stroke) and secondary (composite vascular) out-
comes of interest at these loci, results were not significant across separate cohorts, suggesting
potential ethnic disparities, as demonstrated by the significant association between
Fig 4. Epigenome-wide Manhattan plot for EUR time to composite vascular event. Horizontal line is indicative of epigenome-wide significance threshold (p�
1.06e-07).
https://doi.org/10.1371/journal.pone.0254562.g004
Fig 5. Differentially expressed down-regulated genes from FUMA. Red bars are indicative of statistically significant
differentially expressed tissues based on Benjamini-Hochberg adjustment. Significance threshold padj<0.05.
https://doi.org/10.1371/journal.pone.0254562.g005
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cg03584380 and stroke recurrence in the AFR and Spanish cohorts, but not in EUR (p = 4.07e-
01). Within the AFR stratum, an increase in the beta values at the six significant loci were asso-
ciated with shorter duration to recurrent stroke or composite vascular event, thus suggesting
Table 4. Differentially expressed genes from FUMA using GTEx version 8 tissue expression.
General Tissue Type Specific Tissue Type from GTEx N genesa N overlapb pc padj
d
Pancreas Pancreas 9668 37 5.64E-10 3.05E-08
Brain Putamen basal ganglia 7853 31 4.49E-08 2.42E-06
Heart Left ventricle 9531 33 2.85E-07 1.54E-05
Liver Liver 8059 29 1.62E-06 8.75E-05
Brain Amygdala 7751 28 2.77E-06 1.50E-04
Brain Caudate basal ganglia 6927 26 4.26E-06 2.30E-04
Brain Hippocampus 7571 27 6.53E-06 3.52E-04
Brain Nucleus accumbens basal ganglia 6479 24 1.72E-05 9.30E-04
Brain Anterior cingulate cortex BA24 6725 23 1.10E-04 5.93E-03
Brain Substantia nigra 7223 24 1.11E-04 6.02E-03
Muscle Skeletal 6908 22 5.03E-04 2.72E-02
Blood Whole blood 6940 22 5.38E-04 2.91E-02
Brain Hypothalamus 5967 20 5.43E-04 2.93E-02
aThe number of background genes expressed in specific tissue from GTEx version 8.
bThe number of overlap occurring between input genes and background.
cUnadjusted p-value from the hypergeometric test performed in FUMA.
dBenjamini-Hochberg adjusted p-value.
https://doi.org/10.1371/journal.pone.0254562.t004
Table 5. Significant WGCNA module-trait associations.
Strata Module Trait r pa
AFR bisque4 Previous number of strokes -0.90 5.00E-27
AFR coral2 Prothrombin fragments 1 + 2 -0.79 8.00E-17
AFR pink4 Thrombomodulin -0.77 1.00E-15
AFR coral Thrombin-antithrombin complex -0.73 3.00E-13
AFR yellowgreen Triglycerides -0.71 2.00E-12
AFR lightsteelblue Tissue plasminogen activator -0.68 3.00E-11
AFR darkturquiose Myocardial infarction 0.51 4.00E-06
EUR turquoise Composite endpoint 0.44 5.00E-06
EUR turquoise VISP recurrent stroke 0.43 8.00E-06
AFR honeydew1 Myocardial infarction 0.49 9.00E-06
AFR blue2 Myocardial infarction -0.49 1.00E-05
AFR coral1 Myocardial infarction -0.48 2.00E-05
AFR lightcyan1 Myocardial infarction -0.48 2.00E-05
AFR lightslateblue Myocardial infarction 0.48 2.00E-05
AFR coral Thrombomodulin -0.43 1.00E-04
AFR mediumpurple2 Thrombin-antithrombin complex -0.44 1.00E-04
AFR royalblue Myocardial infarction -0.42 3.00E-04
EUR cyan Composite endpoint 0.34 5.00E-04
AFR thistle3 Hypertension 0.39 7.00E-04
EUR cyan Total plasma homocysteine 0.33 8.00E-04
aStatisitical significance (bold): p� 3.93e-09.
https://doi.org/10.1371/journal.pone.0254562.t005
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that increased methylation at these loci could be indicative of earlier event recurrence. Three
of these loci have implications in the phosphatidylinositol pathway, while the remaining three
loci were located in genes or gene families linked to cardiovascular traits including the patho-
genesis of cardiac disease and diabetes [25], regulation of hyperlipidemia and arteriosclerosis
[26], and insulin sensitivity [27].
cg03584380 was the only locus replicated in our analyses. This methylation site is located in
the first intron of ZDHHC6, the gene which encodes palmitoyltransferase ZDHHC6 [28] and
mediates the palmitoylation of critical endoplasmic reticulum (ER) proteins, including cal-
nexin and the inositol 1,4,5-trisphosphate receptor (ITPR1) [29]. Calnexin is an ER chaperone
that has been implicated in cardiomyocyte viability and in ER stress, a prominent clinical fea-
ture of cardiovascular disease [29], while ITPR1 mediates the influx and release of intracellular
Ca2+ and is regulated by the palmitoylation cascade of ZDHHC16/ZDHHC6 [30, 31]. Addi-
tionally, ITPR1 can be phosphorylated by Akt kinase and further regulated by phosphatidyli-
nositol 3-kinase (PI3K) [32]. Results from the ENCODE annotation suggest this region
around cg03584380 is an active regulatory site. There are several active promoters for both the
ZDHHC6 and VTI1A genes as indicated by the red bars in Fig 2 in the chromatin state seg-
mentation by the Hidden Markov Model (HMM) track, as well as a CpG island just down-
stream of this locus. Furthermore, there is evidence of increased H3K27 (lysine 27 of the H3
histone) acetylation, which also indicates enhanced transcription. Therefore, it is plausible that
cg03584380 could regulate chromatin and histone states related to transcription and transcrip-
tion factor binding, although future gene expression and functional work is needed.
Although the association between cg04059318 and AFR stroke recurrence was not validated
in the EUR only analysis (p = 7.34e-02) or look-up efforts (p = 6.65e-01), it was the most statis-
tically significant association detected in the VISP survival analysis. cg04059318 is located
within the 5’ untranslated region of PTEN and within an intron of KLLN. KLLN encodes
KILLIN, a DNA-binding protein that inhibits DNA synthesis and mediates p53/TP53-induced
apoptosis [28]. PTEN encodes PTEN, a tumor suppressor that regulates angiogenesis [33] and
has been associated with a number of stroke-related clinical traits including triglycerides [34]
and type 2 diabetes [35]. PTEN negatively regulates the Akt signaling pathway through intra-
cellular phosphatidylinositol 3-phosphate (PI3P), which is of interest due to the neuroprotec-
tive properties of Akt against ischemia-induced damage [36, 37]. A third locus involved in the
phosphatidylinositol pathway was identified in the composite vascular event analysis.
cg00076998 is located upstream of PIK3CB, which encodes the catalytic subunit of phosphati-
dylinositol 3-kinase, beta (PI3Kβ). PI3K activates cellular signaling cascades through the gen-
eration of phosphatidylinositol (3,4,5)-trisphosphate and recruitment of Akt and
phosphoinositide-dependent kinase-1 [38]. PI3K is involved in platelet activation signaling
triggered by G-protein coupled receptors [28] and is required for platelet-induced aggregation
induced by thrombin and thromboxane A2 (TxA2) [39]. PI3K/Akt signaling has been
observed in regulation of vascular tone, or the degree of vasoconstriction experienced by a
blood vessel, in both vascular endothelium and smooth muscle cells [40]. Exposure to homo-
cysteine, a well-documented risk factor for atherosclerosis and stroke [41, 42], in endothelial
cells can form the intermediate S-nitroso-homocysteine, a vasodilator implicated in reducing
vascular tone and altering arteriole calcium levels [40] Collectively, these associations have
identified a novel association with ZDHHC6 and implicate PI3K/Akt signaling in time to
stroke and/or vascular event following stroke [43, 44]. These findings could in part, help
explain the ethnic disparities in stroke severity and recovery seen in African American
patients; however, further functional analyses are needed to confirm the biological significance
of our results.
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cg02365967 was the only locus identified in our EUR cohort (composite vascular event;
AFR composite p = 2.54e-01), and was the sole locus that exhibited hypermethylated beta val-
ues (mean β = 0.9411). Increased beta values at this locus were associated with longer duration
to event, which differed from the other identified loci. cg02365967 is located in exon 35 of
HERC2, which encodes the ubiquitin-protein ligase HERC2. This protein regulates ubiquitin-
dependent retention of repair proteins and is a binding protein with SIRT1, a NAD-dependent
protein deacetylase that plays a vasoprotective role in endothelial cells [45]. Increased levels of
SIRT1 have been described to promote endothelial angiogenesis, enhance vasodilation, and
suppress vascular inflammation [45]. Overexpression of SIRT1 in murine endothelial cells pre-
vented hypertension and adverse arterial remodeling; however, a knockdown of HERC2 abol-
ished any beneficial effects of SIRT1 [45], suggesting a neuroprotective regulatory role of
HERC2.
Network analyses using WGCNA, identified six statistically significant associations between
modules and clinical traits in the AFR stratum, including a correlation between a module com-
prised of 58 methylation loci within 38 genes and the previous number of strokes prior to
VISP enrollment variable. Of these genes, A2ML1, AGGF1, CBS, ECE1, GABRB3, GALNT2,
MRPS6/SLC5A3, and SPG7 had documented associations with hypertension, ischemic stroke
and methionine metabolism, atherosclerosis, and early-onset MI [46–48]. GO term enrich-
ment of the genes identified in survival analyses, resulted in terms associated with prepulse
inhibition (GO: 0060134), brain morphogenesis (GO: 0048854), axonogenesis (GO: 0007409),
and postsynaptic assembly, organization, and regulation (GO: 0098698, GO: 2000463, GO:
0098815, and GO: 0099084). Prepulse inhibition (PPI) describes the regulated transmission of
sensory information, while disrupted PPI has been linked to neurological disorders including
Tourette’s syndrome and Schizophrenia [49]. Brain morphogenesis generates and organizes
anatomical structures of the brain, which can be a crucial process after ischemia. Axonogen-
esis, or the de novo generation of a neuron’s long process [50], requires the melatonin MT2
receptor [51]. Deficits in MT2 signaling have been observed in a number of neurological disor-
ders, including Alzheimer’s disease, suggesting that axonogenesis may be beneficial in regard
to the outcome of these disorders [51]. The GO results, in addition to the differential gene
expression analysis in GTEx tissues, provide evidence of altered cerebro- and cardiovascular
regulation.
Recurrent stroke is a vastly understudied phenotype and its etiology is not well understood.
The utilization of this phenotype is a strength of this study; however, one limitation is the lack
of formally adjudicated ischemic stroke subtype. We can conclude that due to the inclusion
and exclusion criteria of VISP, the enrollment strokes were most likely lacunar or small vessel
infarctions. DNA methylation profiles were generated from whole blood samples. Although
not optimal due to cellular heterogeneity, whole blood provides a valuable resource that is
potentially available for replication studies and represents a minimally invasive source for
potential biomarker testing. To overcome this limitation, cellular proportions were calculated
in silico, and used as covariates in the Cox PH models. Although our analyses detected seven
statistically significant loci and replicated cg03584380 in the Vall d’Hebron University Hospital
cohort, one constraint of this study that could not be fully addressed was the limited statistical
power due to the modest sample sizes of both the discovery cohort and replication cohort. Fur-
thermore, previous studies have shown that global methylation patterns differ across ethnici-
ties, as well as within ethnic subgroups. In a study of 573 individuals from diverse Latino
ethnic sub-groups, genetic ancestry explained approximately 75% of the variation in methyla-
tion between the sub-groups [52]. Therefore, the use of cohorts from different races or ethnici-
ties should allow for the identification of methylation sites with global implications (affecting
most ethnicities similarly) but will limit our ability to identify race/ethnicity-specific
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associations. In conclusion, findings from this study provide insight into the relationship
between the degree of DNA methylation and the duration to recurrent stroke and vascular
event following a stroke and lay the foundation for further studies investigating these out-
comes in diverse populations.
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